RxDoctor Payments Data

Bharat Motwani, MD

Infectious Disease · Davenport, IANPI 1902885445

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $990 of the $1,483 with a category attached, or 66.8%. 15 manufacturers reported payments, led by Astellas Pharma US Inc at 25.4% of the total. Reporting peaked in 2019 at $476 and has fallen 94.3% since, to $27 in 2025.

$1,483in general payments, 2019–2025

Across 62 payments — averaging $23.93 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Astellas Pharma US Inc$377
  • Viiv Healthcare Company$197
  • Pfizer$192
  • Gilead$134
  • Merck$130
  • AbbVie$122
  • plus $332 from 9 others

What the payments were for

  • Consulting fees$1007%
  • Food & beverage$99067%
  • Education$39327%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,483 in reported general payments places this provider in the 85th percentile of 58 infectious disease providers in Iowa.

See all infectious disease providers in Iowa

Medicare billing

Part B allowed, 2024
$444,896
Medicare patients
536
Services billed
14,354

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
BiktarvyBictegrav/Emtricit/Tenofov Ala44$165,831
OdefseyEmtricitab/Rilpiviri/Tenof Ala35$120,200
GenvoyaElviteg/Cob/Emtri/Tenof Alafen21$97,892
TriumeqAbacavir/Dolutegravir/Lamivudi13$45,795
StribildElviteg/Cob/Emtri/Tenofo Disop11$43,183
DescovyEmtricitabine/Tenofov Alafenam16$36,556
IsentressRaltegravir Potassium12$27,321
PrezcobixDarunavir/Cobicistat11$24,562
TivicayDolutegravir Sodium11$22,538
Lupron DepotLeuprolide Acetate12$21,782
Atazanavir Sulfate23$15,273
Etravirine12$13,509
JardianceEmpagliflozin11$6,611
Rifampin12$2,408
Fluconazole48$2,075

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GileadBiktarvy, Genvoya, Stribild, Descovy$134$343,46292 claims
Viiv Healthcare CompanyTriumeq, Tivicay$197$68,33324 claims
MerckIsentress$130$27,32112 claims
Johnson & JohnsonPrezcobix$42$24,56211 claims
AbbVieLupron Depot$122$21,78212 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 58 infectious disease providers in Iowa.

Other infectious disease in Davenport

See the full list for Iowa

Where these figures come from

Is this you, or does something look wrong? →